Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting by Javier Puente, Enrique Grande, Ana Medina, Pablo Maroto, Nuria Lainez, Jose Angel Arranz

Get full text

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment by Elisabet Cantó, Georgia Anguera, Natalia Jiménez, Begoña Mellado, Ona Ramírez, Anais Mariscal, Pablo Maroto, Silvia Vidal

Get full text

Cabozantinib for the treatment of solid tumors: a systematic review by Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Daniel Castellano

Get full text

Cabozantinib combination therapy for the treatment of solid tumors: a systematic review by Daniel Castellano, Andrea B. Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Pablo Maroto

Get full text

Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy by Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal

Get full text

Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group by Antonio Gómez Caamaño, Ana M. García Vicente, Pablo Maroto, Alfredo Rodríguez Antolín, Julián Sanz, María Almudena Vera González, Miguel Ángel Climent, on behalf of the Spanish Oncology Genitourinary (SOGUG) Multisiciplinary Working Group

Get full text

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE by Javier Puente, Urbano Anido, Miguel Ángel Climent, Enrique Gonzalez-Billalabeitia, Nuria Lainez, Julio Lambea, José Pablo Maroto, Maria Jose Mendez-Vidal, Álvaro Montesa, Angel Rodriguez, Curro Zambrana, Aránzazu González-del-Alba

Get full text

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study by Magnus Lindskog, Anna Laurell, Anders Kjellman, Bohuslav Melichar, Pablo Maroto Rey, Henryk Zieliński, Felipe Villacampa, Pierre Bigot, Bajory Zoltan, Omi Parikh, David Vazquez Alba, Åsa Jellvert, Tibor Flaskó, Enrique Gallardo, Maria José Ribal Caparrós, Gunta Purkalne, Peter Suenaert, Alex Karlsson-Parra, Börje Ljungberg

Get full text

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

Get full text

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

Get full text